Many Boston Scientific Corporation (NYSE:BSX) insiders ditched their stock over the past year, which may be of interest to ...

Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” third-quarter 2025 ...

Boston Scientific Corporation (NYSE:BSX) is one of the best healthcare AI stocks to buy now. On December 12, TD Cowen reaffirmed a Buy rating on Boston Scientific Corporation (NYSE:BSX) and kept a ...

Boston Scientific (BSX) has quietly outperformed many medtech peers this year, and with the stock hovering near 96 dollars ...

When assessing Boston Scientific’s valuation against the S&P 500, the stock presents as notably expensive across key metrics. The company’s price-to-sales (P/S) ratio stands at 8.3, substantially ...

In the preceding three months, 6 analysts have released ratings for Boston Scientific (NYSE:BSX), presenting a wide array of perspectives from bullish to bearish. Summarizing their recent assessments, ...

Boston Scientific is a Buy with a $109 target and 14% upside from strong demand, Q3 beats, raised FY25 guidance, and growth ...

CHONGQING, CHINA - APRIL 20: In this photo illustration, the logo of Boston Scientific Corporation is displayed on a smartphone screen, with the company's branding and slogan Advancing science for ...

Boston Scientific Corporation is rated a Hold with double-digit revenue growth and margin expansion. Learn more about BSX ...

Boston Scientific (NYSE: BSX) has outperformed the market over the past 15 years by 7.91% on an annualized basis producing an average annual return of 20.24%. Currently, Boston Scientific has a market ...